期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

如何优化三阳性乳腺癌的临床治疗方案

原文传递
导出
摘要 激素受体（HR）和人表皮生长因子受体2（Her-2）是影响乳腺癌患者预后的两个重要生物学指标，通常两者在乳腺癌组织中不同时表达。大量的研究显示，HR阴性或Her-2扩增或过表达（简称Her-2高表达）的乳腺癌，组织分化程度低，对内分泌治疗效果差，患者的无病生存期（DFS）和总生存期（OS）均较短。
作者 王宁 王雅杰
机构地区 第二军医大学长海医院肿瘤科
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2010年第4期241-243,共3页 Chinese Journal of Oncology
基金 2006年上海市科学技术委员会科技攻关计划（No.06DZ19505）
关键词 乳腺肿瘤 药物疗法 联合 人表皮生长因子受体2 受体 雌激素 受体 孕激素 Breast neoplasms Drug therapy,combination Her-2 Receptors, estrogen Receptors,progestin
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1Prat A,Baselga J.The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.Nat Clin Pract Oncol,2008,5:531-542.
  • 2袁中玉,王树森,朱美琴,郑磊,罗文标,周中梅,管忠震.不同分子亚型乳腺癌的临床特征和预后[J].中华肿瘤杂志,2008,30(6):456-461. 被引量：55
  • 3Ellis MJ,Tao Y,Young O,et al.Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.J Clin Oncol,2006,24:3019-3025.
  • 4Dowsett M,Ebbs SR,Dixon JM,et al.Biomarker changes during neoadjuvant anastrozole,tamoxifen,or the combination:influence of hormonal status and HER-2 in breast cancer:a study from the IMPACT trialists.J Clin Oncol,2005,23:2477-2492.
  • 5Van Calster B,Vanden Bempt I,Drijkoningen M,et al.Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status;triple positive tumours are more likely lymph node positive.Breast Cancer Res Treat,2009,113:181-187.
  • 6Bartlett JM,Ellis IO,Dowsett M,et al.Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor(ER)negative,but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.J Clin Oncol,2007,25:4423-4430.
  • 7Arpino G,Wiechmann L,Osborne CK,et al.Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family:molecular mechanism and clinical implications for endocrine therapy resistance.Endocr Rev,2008,29:217-233.
  • 8Smith I,Procter M,Gelber RD,et al.2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer:a randomised controlled trial.Lancet,2007,369:29-36.
  • 9马传栋,沈坤炜,沈镇宙.拉帕替尼治疗乳腺癌的研究进展[J].中华肿瘤杂志,2008,30(5):321-324. 被引量：9

二级参考文献36

  • 1王莉萍,沈坤炜,沈镇宙.赫赛汀在乳腺癌新辅助治疗与辅助治疗中的新进展[J].中华肿瘤杂志,2006,28(4):241-243. 被引量：26
  • 2Johnston SR, Leary A. Lapatinib: a novel EGFR/Her2 tyrosine kinase inhibitor for cancer. Drugs Today ( Barc), 2006, 42:441- 453.
  • 3Lackey KE. Lessons from the drug discovery of lapatinib, a dual ErbBl/2 tyrosine kinase inhibitor. Curr Top Med Chem, 2006, 6:435-460.
  • 4Nelson MH, Dolder CR. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother, 2006, 40 : 261-269.
  • 5Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumorderived cell lines in vitro and in vivo. Mol Cancer Ther, 2001, 1 : 85-94.
  • 6Xia W, Liu LH, Ho P, et al. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene, 2004, 23:646-653.
  • 7Xia W, Gerard CM, Liu L, et al. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene, 2005, 24: 6213-6221.
  • 8Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against Her-2- overexpressing and trastuzumab-treated breast cancer cells. Cancer Res, 2006, 66:1630-1639.
  • 9Lipton A, Leitzel K, Ali SM, et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer, 2005, 104:257-263.
  • 10Chu I, Blackwell K, Chen S, et al. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation-and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res, 2005, 65 : 18- 25.

共引文献62

中华肿瘤杂志
2010年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部